You are here

Wireless Vagal Nerve Stimulation System for Treating Atrial Fibrillation

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43HL121970-01
Agency Tracking Number: R43HL121970
Amount: $220,835.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NHLBI
Solicitation Number: PA13-088
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
13739 Sprucewood Cir
Dallas, TX 75240-3629
United States
DUNS: 968130778
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 AUSTIN DUKE
 (919) 614-8833
 austin@roselliniscientific.com
Business Contact
 AUSTIN DUKE
Phone: (214) 922-7527
Email: austin@roselliniscientific.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): Atrial fibrillation (AF) is the most common cardiac arrhythmia, and is associated with substantial risk of morbidity and mortality. AF currently affects more than 2.5 million Americans and the affected population is steadily growing with our aging society. AF independently increases the risk of stroke by 4- to 5-fold, is an independent risk factor for stroke recurrence, and is responsible for at least 15-20% of all ischemic strokes. In addition to its associated health risks and diminished quality of life, AF is a financial burden on the US Healthcare system, with annual Medicare costs currently estimated at 16 billion. Over the past decade, neuromodulator emerged as an alternative to antiarrhythmic medications and ablative procedures for the treatment of some forms of AF. Applying low levels of electrical stimulation to the vagus nerves inhibits AF inducibility. This innovative form of neural cardiac control is a non-pharmacological, non- ablative modality for the

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government